What You Need to Know About Bio-Rad Laboratories, Inc.'s Q3 Earnings
Bio-Rad Laboratories, Inc.'s fiscal Q3 earnings report was released on Tuesday, August 04. Let's dive in to see if (BIO) missed or beat analyst's expectations.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Michael Rose
Michael Rose
Michael Rose
Jenna Brashear
| Share Statistics | BIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $10,008.3 | $3,076.5 | 77% |
|
| Shares Out (Mil) | 26.8 | 96.5 | 35% |
|
| Institutional Ownership | 45.9% | 90.0% | 20% |
|
| Float (Mil) | 20.9 | 71.5 | 30% |
|
| Beta | 1.05 | 1.22 | 64% |
|
| Avg Daily Volume (000s) | 237 | 710 | 46% |
|
| Price Change (52-week) |
30.6% | 89.4% | 69% |
|
| Growth | BIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 0.3% | 7.8% | 18% |
|
| Net Income (5yr) | (27.6%) | (13.7%) | 15% |
|
| EPS (5yr) | (26.1%) | 0.7% | 10 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 59.5% | (15.0%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 5 | |
| Current EPS | $2.231 | $9.483 | $10.028 | |
| Month Ago EPS | $2.311 | $9.002 | $9.722 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | $2.361 | $9.092 | $9.802 | |
| Year/Year Chg | (83.9%) | (65.9%) | (64.2%) | |
| Financials | BIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,589 | $800 | 64% |
|
| Net Income (TTM) (Mil) | $222 | ($31) | 69% |
|
| EPS (TTM) | $8.263 | ($0.300) | 92% |
|
| Operating Cash Flow (TTM) (Mil) | $493 | $47 | 71% |
|
| Net Cash Flow (TTM) (Mil) | $147 | $5 | 81% |
|
| Long-Term Debt (Q1) (Mil) | $936 | $270 | 65% |
|
| Enterprise Value (Q1) (Mil) | $9,158 | $3,795 | 72% |
|
| Valuation | BIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.40 | 3.68 | 36% |
|
| P/E | 45.6 | 39.8 | 82% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.5 | na |
|
| Ratios | BIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 52.0% | 47.7% | 64% |
|
| Net Margin | 8.6% | (3.2%) | 59% |
|
| ROA | 2.2% | (4.3%) | 57% |
|
| ROE | 3.1% | (7.9%) | 40% |
|
| Liabilities to Assets | 30.0% | 42.0% | 21% |
|
| F-Score | 5 | 5 | 50% |
|
Bio-Rad Laboratories, Inc. did not pass any screens on 8/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors